3 December 2015 - NHS cost regulators are planning to reject Alexion’s therapy for an ultra-rare bone disorder called paediatric-onset hypophosphatasia, which affects just seven people a year in England.

For more details, go to: http://www.pharmatimes.com/Article/15-12-03/NICE_turns_down_Alexion_s_£366K-a-year_bone_disease_drug.aspx